FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial...

July 12
Last Trade: 3.36 0.38 12.75

GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation data...Read more

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression...

July 11
Last Trade: 2.31 0.30 14.93

Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...Read more

Biodexa Pharmaceuticals Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous...

July 11
Last Trade: 1.06 -0.02 -1.85

CARDIFF, UK / ACCESSWIRE / July 11, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making good progress with eRapa™,...Read more

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis

July 12
Last Trade: 170.26 0.35 0.21

Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission from week 12 through week 521 The safety profile of upadacitinib in patients with GCA was generally consistent...Read more

Can-Fite BioPharma Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

July 11
Last Trade: 3.47 0.21 6.44

PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it  has submitted an...Read more

Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec

July 10
Last Trade: 142.07 2.28 1.63

Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the...Read more

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...


Biggest Gainers

CompanyChangeLast Trade
Regeneron Pharmaceuticals 19.78 1.83 $1,100.05
Eli Lilly 14.03 1.50 $948.17
Bio-Rad Laboratories 8.75 2.96 $304.28
Medpace 8.01 1.84 $443.00
UnitedHealth 7.08 1.40 $511.44
HCA Healthcare 6.88 2.17 $324.39
Legend Biotech 5.87 12.10 $54.37
Third Harmonic Bio 5.78 80.28 $12.98
Amgen 5.74 1.77 $330.83
Corbus Pharmaceuticals 5.56 10.42 $58.90
Thermo Fisher Scientific 5.40 1.00 $548.09
Charles River Laboratories 5.31 2.52 $216.19
ResMed 5.05 2.53 $204.83
IDEXX Laboratories 4.96 1.02 $492.74
Krystal Biotech 4.73 2.38 $203.13
IQVIA 4.73 2.16 $224.17
argenx 4.70 1.02 $466.42
Penumbra 4.54 2.44 $190.83

Highest Volume

CompanyVolumeLast Trade
Qualigen Therapeutics 410,590,322 $0.43
Ginkgo Bioworks 60,165,948 $0.29
Vyome 36,361,564 $0.22
Pfizer 25,136,124 $28.92
Kazia Therapeutics 24,431,975 $0.90
Walgreens Boots Alliance 17,138,399 $11.50
Bristol-Myers Squibb 15,081,044 $40.44
ENDRA Life Sciences 13,609,083 $0.09
PacBio 11,399,671 $1.68
Cybin 10,979,050 $0.32
10,133,422 $8.36
Geron 9,212,525 $4.71
Longeveron 7,617,274 $4.39
Therapeutic Solutions 7,413,100 $0.0006
Iovance Biotherapeutics 7,051,290 $8.73
Novavax 7,034,135 $13.11
China SXT Pharmaceuticals 6,928,154 $1.28
CVS Health 6,832,098 $59.03
Teva Pharmaceutical 6,791,263 $17.28
  • Upcoming FDA Catalysts

    • Phathom Pharmaceuticals (NASDAQ: PHAT) PDUFA Date

      July 19, 2024
    • Adaptimmune Therapeutics (NASDAQ: ADAP) PDUFA Date

      August 4, 2024
    • Humacyte (NASDAQ: HUMA) PDUFA Date

      August 10, 2024
    • Citius Pharmaceuticals (NASDAQ: CTXR) PDUFA Date

      August 13, 2024
    • CymaBay Therapeutics (NASDAQ: CBAY) PDUFA Date

      August 14, 2024
    • Ascendis Pharma (NASDAQ: ASND) PDUFA Date

      August 14, 2024

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...


Featured Stock


Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....


Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...


Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...


Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: